Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2025 07:00 ET | Source: Algernon Pharmaceuticals Inc.

Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment

VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
April 01, 2024 07:00 ET | Source: Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
November 16, 2022 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
December 10, 2015 11:58 ET | Source: MicroTransponder

MicroTransponder Clinical Trial Results Published in Stroke After Company Completes a $5.5M Round of Funding

DALLAS, TX--(Marketwired - December 10, 2015) - MicroTransponder, Inc., (www.microtransponder.com) a privately-held medical device company, is pleased to announce that its successful stroke...